恶性Bethesda III结节与Bethesda V/VI结节相比呈惰性行为
这项单中心回顾性分析纳入556例甲状腺癌患者,比较初始细胞学为Bethesda III、IV、V、VI级的临床行为差异。Bethesda III级与V/VI级组织学相似但预后更好:缓解概率更高(62% vs 46%),复发可能性更低(8% vs 24%),达缓解时间更短(中位1218 vs 1682天),校正后结果不变。
要点
- Bethesda III级甲状腺癌缓解概率高于V/VI级(62% vs 46%,P < .03)。
- Bethesda III级复发可能性低于V/VI级(8% vs 24%,P < .001)。
- Bethesda III级诊断至手术间隔长于V/VI级(中位78 vs 41天,P < .001)。
核心结论
- Bethesda III级细胞学癌症尽管组织学相似,但临床表型侵袭性更低、预后优于V/VI级。
- Bethesda III级诊断至手术间隔更长,但达缓解时间更短。
- 初始细胞学诊断可能指导管理。
研究设计与样本
- 单中心学术医疗中心的回顾性分析。
- 纳入组织学诊断为甲状腺癌且初始细胞学为Bethesda III、IV、V或VI级的患者,共556例,其中Bethesda III级87例、IV级109例、V级120例、VI级240例。
主要发现
- Bethesda III级与V/VI级相似,与IV级相比以甲状腺乳头状癌为主。
- Bethesda III级诊断至手术间隔长于V/VI级(中位78 vs 41天,P < .001)。
- Bethesda III级缓解概率高于V/VI级(62% vs 46%,P < .03)。
- Bethesda III级复发可能性低于V/VI级(8% vs 24%,P < .001)。
- Bethesda III级达缓解时间短于V/VI级(中位1218 vs 1682天,P = .02),校正年龄、性别、放射性碘治疗、手术方式和肿瘤大小后结果不变。
关键数值与推荐
- Bethesda III级缓解概率62% vs V/VI级46%(P < .03)。
- Bethesda III级复发可能性8% vs V/VI级24%(P < .001)。
- Bethesda III级诊断至手术间隔中位78天 vs V/VI级41天(P < .001)。
- Bethesda III级达缓解时间中位1218天 vs V/VI级1682天(P = .02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Bethesda system classifies all fine-needle aspiration specimens into 1 of 6 categories. We speculated that cancers within each Bethesda category would have distinct clinical behavior. METHODS: This is a retrospective analysis of patients from a single academic medical center with a histologic diagnosis of thyroid cancer who had an initial diagnosis of Bethesda III, IV, V, or VI cytology. RESULTS: A total of 556 cases were included, with 87 cases of Bethesda III, 109 cases of IV, 120 cases of V, and 240 cases of VI. Bethesda III showed similarities with V/VI compared to IV with a predominance of papillary thyroid cancer. The interval from diagnosis to surgery was longer in Bethesda III compared to Bethesda V/VI (median 78 vs 41 days, P < .001) (Fig. 1). Yet, patients with Bethesda III had a higher probability of achieving remission (62% vs 46%, P < .03), a lower possibility of recurrence (8% vs 24%, P < .001), and a shorter interval to achieve remission (median 1218 vs 1682 days, P = .02) compared to Bethesda V/VI, which did not change after adjusting for age, sex, radioactive iodine therapy, mode of surgery, and tumor size. More than 70% of Bethesda III that later presented with recurrence had T3/T4 disease or distant metastasis. CONCLUSION: Cancers with Bethesda III cytology had a less aggressive clinical phenotype with better prognosis compared to V/VI despite histological similarities. The time to remission was shorter in Bethesda III despite a longer interval between diagnosis and surgery. The initial cytological diagnosis may guide management.
引用
- Endo M, Peng J, Nabhan FA, et al. Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules. J Clin Endocrinol Metab. 2024. PMID: 38415340. doi:10.1210/clinem/dgae108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。